Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma

Published:2014-02-24 Issue:4 Volume:89 Page:349-354
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Lazaryan Aleksandr¹,Hussein Mohamad A.²,Reu Frederic J.¹,Faiman Beth¹,Habecker Becky¹,Ann Karam Mary¹,Reed Janice¹,Hamilton Kimberly¹,Waksman Joel³,Bruening Kellie⁴,Srkalovic Gordan⁵,Andresen Steven¹,Kalaycio Matthew¹,Sweetenham John W.⁶,Sobecks Ronald¹,Dean Robert¹,Knight Robert²,Zeldis Jerome B.²,Baz Rachid⁷

Affiliation:

1. Taussig Cancer Institute, Cleveland Clinic; Cleveland Ohio

2. Celgene Corporation; Summit New Jersey

3. Brightech International; Somerset New Jersey

4. Quantitative Health Sciences, Cleveland Clinic; Cleveland Ohio

5. Medical Oncology/Hematology; Sparrow Cancer Center; Lansing Michigan

6. UC San Diego Nevada Cancer Institute; Las Vegas Nevada

7. Department of Hematologic Malignancies; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

Publisher

Wiley

Subject

Hematology